8-K: Catalyst Pharma Posts Record 2025 Results, Strong 2026 Outlook

Catalyst Pharmaceuticals reported record full-year 2025 revenues of $589.0 million, a 19.8% year-over-year increase, and provided 2026 revenue guidance of $615 million to $645 million.

Summary

• Full year 2025 total revenues reached a record $589.0 million, marking a 19.8% year-over-year growth.
• Fourth quarter 2025 total revenues were $152.6 million, an increase of 7.6% year-over-year.
• FIRDAPSE product revenue, net grew by 17.1% to $358.4 million for the full year 2025 and 18.3% to $97.6 million in Q4 2025.
• AGAMREE product revenue, net surged by 154.3% to $117.1 million for the full year 2025 and 67.5% to $35.3 million in Q4 2025, reflecting strong market adoption.
• GAAP net income for full year 2025 increased by 30.8% to $214.3 million, with diluted EPS of $1.68.
• Non-GAAP net income for full year 2025 rose by 25.3% to $346.2 million, with diluted EPS of $2.72.
• Cash and cash equivalents stood at $709.2 million as of December 31, 2025, a 37.0% increase from the prior year.
• The company initiated a $200 million share repurchase program in Q4 2025, having repurchased 1,740,713 shares for approximately $39.9 million to date.
• Updated NCCN guidelines now include VGCC antibody screening for SCLC patients for cancer-associated LEMS and recommend FIRDAPSE as a supportive care treatment.
• FIRDAPSE patent litigation with Teva and Lupin was settled, with one remaining case against Hetero USA, Inc. scheduled for trial on March 23, 2026.
• Sub-licensee KYE Pharmaceuticals received Health Canada approval for AGAMREE for Duchenne muscular dystrophy (DMD).
• Sub-licensee DyDo Pharma launched FIRDAPSE 10 mg in Japan for LEMS.
• The overall royalty rate for FIRDAPSE net U.S. sales will decrease to 6% starting January 26, 2026, down from a previous maximum of 18.5%.
• FYCOMPA product revenue, net declined by 17.4% to $113.3 million for the full year 2025 and to $19.6 million in Q4 2025 due to generic competition.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to record financial performance, strong growth in key rare disease products, a healthy cash position, and a positive outlook for 2026, despite challenges with FYCOMPA generics.

Positives

• Achieved record total revenues of $589.0 million for full year 2025, representing 19.8% year-over-year growth.
• FIRDAPSE and AGAMREE demonstrated robust organic growth, with FIRDAPSE revenue up 17.1% and AGAMREE revenue up 154.3% for the full year 2025.
• GAAP net income increased by 30.8% to $214.3 million for full year 2025, reflecting strong profitability.
• Cash and cash equivalents grew by 37.0% to $709.2 million, indicating a strong balance sheet.
• The company initiated a $200 million share repurchase program, demonstrating confidence in its long-term financial outlook and returning value to shareholders.
• Favorable changes in FIRDAPSE royalty agreements will reduce the overall royalty rate to 6% from January 26, 2026, improving future margins.
• Expanded clinical awareness and diagnostic rates for cancer-associated LEMS through updated NCCN guidelines, supporting FIRDAPSE's market.
• International expansion with Health Canada approval for AGAMREE and FIRDAPSE launch in Japan by sub-licensees.
• Recognized as one of North America's Fastest-Growing Companies by Deloitte Technology Fast 500 and among Forbes' Americas Most Successful Small-Cap Companies.

Negatives

• FYCOMPA product revenue, net decreased by 17.4% for full year 2025 and significantly in Q4 2025 due to the entry of multiple generic versions.
• Fourth quarter 2025 operating income decreased by 1.6% to $61.8 million compared to Q4 2024, primarily impacted by FYCOMPA generic entry.
• GAAP net income for Q4 2025 decreased to $52.7 million from $55.9 million in Q4 2024, also impacted by generic competition for FYCOMPA.

Risks

• The outcome of the pending Paragraph IV litigation relating to FIRDAPSE against Hetero USA, Inc. is uncertain and could adversely affect the company if the results are adverse.
• There is a potential for impairment of the company's intangible asset relating to the acquisition of FYCOMPA if revenues from sales of this product decline more than currently expected due to generic competition.
• The company's revenue forecasts for 2026 may not prove to be accurate, and actual results could differ materially.
• There is no assurance that the company will continue to be profitable and cash flow positive in 2026 and beyond.
• The company's ability to complete any acquisitions of additional products, and the timing and success of such acquisitions, are uncertain.

Future Outlook

The company forecasts full year 2026 total revenues to be between $615 million and $645 million, driven by continued robust growth in FIRDAPSE and AGAMREE. FIRDAPSE product revenue is expected to be between $435 million and $450 million, reflecting 21.4% to 25.6% growth, supported by life-cycle management initiatives. AGAMREE product revenue is projected to be between $140 million and $150 million, representing 19.6% to 28.1% growth due to continued market adoption. FYCOMPA revenue is expected to be $40 million to $45 million despite generic competition. Research and development expenses are anticipated to be between $17.5 million and $22.5 million, excluding acquisitions, while selling, general, and administrative expenses are expected to increase to support commercial activities and an expanded business development strategy focusing on development-stage opportunities with established proof of concept.

Management Comments

• "Our 2025 performance is a reflection of Catalysts organic growth of our promoted products, FIRDAPSE and AGAMREE, and our continued commercial success."
• "Achieving total revenues for 2025 of $589.0 million demonstrates the strength of our scalable business model and our continued dedication to patient care."
• "Looking forward, our core commercial capabilities and our exploration of lifecycle management opportunities within our portfolio will continue to create value."
• "Based on our recent progress and considering the growth opportunities that we see for both FIRDAPSE and AGAMREE, we anticipate 2026 will prove to be another exceptional year, as reflected in our 2026 revenue guidance."

Industry Context

StockSavvy.ai notes that Catalyst Pharmaceuticals continues to demonstrate strong execution in the rare disease segment, with FIRDAPSE and AGAMREE driving significant organic growth. This performance is particularly noteworthy given the increasing pressure from generic competition on its FYCOMPA product, highlighting the company's successful pivot and focus on its core orphan drug franchises. The strategic expansion into development-stage assets with established proof of concept aligns with broader industry trends of biopharmaceutical companies seeking to replenish pipelines and maintain growth in specialized markets.

Comparison to Industry Standards

• NA

Legal Proceedings

• FIRDAPSE patent litigation with Teva Pharmaceuticals USA, Inc. and Lupin Pharmaceuticals, Inc. has been settled.
• One FIRDAPSE patent case remains pending against Hetero USA, Inc., with the trial currently scheduled to start on March 23, 2026, prior to the expiration of the automatic 30-month stay on May 26, 2026. The outcome of this matter cannot be assured.

Stakeholder Impact

• Shareholders are positively impacted by record revenues and earnings, strong growth prospects for core products, a robust cash position, and the initiation of a $200 million share repurchase program.
• Patients with Lambert-Eaton myasthenic syndrome (LEMS) and Duchenne muscular dystrophy (DMD) benefit from continued commercial success and expanded access to FIRDAPSE and AGAMREE, including new NCCN guidelines for LEMS and Health Canada approval for AGAMREE.
• Employees benefit from the company's strong financial performance and industry recognitions as a 'Best Place to Work'.

Next Steps

• Host a conference call and webcast on February 26, 2026, to discuss the financial results and 2026 guidance.
• Continue enrollment in the SUMMIT study to further demonstrate the clinical value of AGAMREE.
• Execute the business development strategy, including identifying and evaluating immediate and near-term accretive rare disease assets, particularly development-stage opportunities with established proof of concept.
• Proceed with the FIRDAPSE patent litigation trial against Hetero USA, Inc., scheduled to start on March 23, 2026.

Key Dates

Recommendation

The company delivered record full-year 2025 financial results, driven by robust organic growth of its flagship rare disease products, FIRDAPSE and AGAMREE. The 2026 revenue guidance is strong, indicating continued momentum and confidence in its core franchises. A significant cash position, coupled with a share repurchase program, demonstrates financial strength and a commitment to shareholder value. Furthermore, favorable changes in FIRDAPSE royalty rates are expected to enhance future profitability. While generic competition for FYCOMPA presents a headwind, the overall performance and strategic focus on high-growth rare disease assets make this a compelling investment opportunity.

Keywords

Catalyst Pharmaceuticals, CPRX, FIRDAPSE, AGAMREE, FYCOMPA, Rare Disease, Biopharmaceutical, Financial Results, Revenue Guidance, LEMS, Duchenne Muscular Dystrophy, DMD, Patent Litigation, Share Repurchase, Orphan Drugs